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    Pharmacological treatment of ischemic brain injury has been 
under investigation for more than a quarter of century [1]. 
Despite this, we still have little solid evidence that such therapy 
is effective.
    In an article published in this issue of Korean Journal of 
Anesthesiology, Kim et al. [2] provide a fascinating preclinical 
study examining neuroprotective effect of gabapentin on 
ischemic brain. In this issue, Kim et al. make two important 
contributions to our understanding of the effects of gabapentin 
on ischemic brain. First, they show conclusively that gabapentin 
is neuroprotective against focal cerebral ischemia. Second, they 
provide evidence that the neuroprotective effect of gabapentin 
is likely related to expression of Hsp70. 
    The ischemic pathway overlaps greatly with seizure processes 
and therefore anticonvulsants have been proposed as possible 
neuroprotective agents [3]. High-dose gabapentin decreases 
acute seizure frequency and reduce brain atrophy [4]. Gaba-
pentin shows no neuroprotective effects in the treatment of 
cultured neurons exposed to neurotoxic or ischemic insults, 
suggesting that in vivo neuroprotection can be attributed to 
antiseizure effects [5]. The findings of Kim et al. suggests that 
low-dose gabapentin also have neuroprotective effect apart 
from anti-seizure activity. 
    The data of Kim et al. can be interpreted in a different way. 
Gabapentin directly inhibits necrotic responses to focal 
ischemia but fails to inhibit apoptosis that is concurrently 
stimulated, with the net result being neuroprotective in 24 hours. 
Although gabapentin may abate necrotic responses to ischemia, 
anti-apoptotic drug is still required. This holds experimental 
promise, but there are no clinically available anti-apoptotic 
drugs.
    The current study raises several questions. One of the more 
interesting is whether neuroprotection is dependent on some 
particular quality of gabapentin distinct from its capacity to 
prevent seizures. Although Kim et al. shows increase of heat 
shock protein 70, experiment on the neuronal cell death was 
not performed. Further studies with mechanism based on 
examinations of neuroprotective actions should be able to 
reveal the answer to this question. 
    Durability is still questioned. Almost all purported neuro-
protective compounds have failed to provide protection against 
severe ischemic insults when outcome was assessed after 
long postischemic intervals [6,7]. Of note, there have been no 
long-term outcome studies in animals or humans that have 
demonstrated sustained benefit from barbiturates, etomidate, 
or propofol, regardless of duration of the ischemic insult. Long-
term outcome study on the neuroprotective effect of gabapentin 
is required.
    An important question is whether the findings of Kim et 
al. will renew interest in testing neuroprotectants in human 
neuroprotection trials, an effort that had clearly waned after the 
failure of countless clinical studies of stroke neuroprotection. 
If an intervention that has shown effective neuroprotection 
in preclinical studies fails in clinical trials, what then are the 
prospects for demonstrating the neuroprotective efficacy in 
preclinical investigations? Clearly, much more work is needed 116 www.ekja.org
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before gabapentin can be evaluated as a neuroprotectant, 
especially considering the large and expensive clinical trial that 
necessarily lies ahead. In today’s environment of outcomes 
research driving evidence-based clinical practice, whether it 
is even possible to obtain good evidence for neuroprotection 
in humans is a matter for debate. Although the contribution of 
Kim et al. is a major step in neuroprotection in the laboratory, 
history teaches us that much more remain to be written in the 
clinic.
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